The quest to overcome resistance to EGFR-targeted therapies in cancer NATURE MEDICINE Chong, C. R., Jaenne, P. A. 2013; 19 (11): 1389–1400

Abstract

All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually develop resistance. An increasing understanding of the number and complexity of resistance mechanisms highlights the Herculean challenge of killing tumors that are resistant to EGFR inhibitors. Our growing knowledge of resistance pathways provides an opportunity to develop new mechanism-based inhibitors and combination therapies to prevent or overcome therapeutic resistance in tumors. We present a comprehensive review of resistance pathways to EGFR-targeted therapies in lung, colorectal and head and neck cancers and discuss therapeutic strategies that are designed to circumvent resistance.

View details for DOI 10.1038/nm.3388

View details for Web of Science ID 000326920300017

View details for PubMedID 24202392

View details for PubMedCentralID PMC4049336